Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.
[BACKGROUND] The relative benefit of neoadjuvant therapies remains controversial for patients with (borderline) resectable pancreatic ductal adenocarcinoma (PDAC).
- 표본수 (n) 1258
- p-value p < 0.05
- p-value p < 0.001
APA
Harada GK, Park J, et al. (2025). Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.. Cancer medicine, 14(23), e71447. https://doi.org/10.1002/cam4.71447
MLA
Harada GK, et al.. "Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.." Cancer medicine, vol. 14, no. 23, 2025, pp. e71447.
PMID
41347669
Abstract
[BACKGROUND] The relative benefit of neoadjuvant therapies remains controversial for patients with (borderline) resectable pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to create a model to predict response to multiagent neoadjuvant chemotherapy (NAC) followed by radiotherapy with elective nodal irradiation (ENI).
[METHODS] Using the National Cancer Database (NCDB), we identified patients with cT1-4N0M0 PDAC diagnosed between 2006 and 2020 treated with multiagent NAC, radiation with ENI, followed by curative resection with nodal dissection. A LASSO logistic regression model was used to predict ypN0 status, with generation of a nomogram and assessment of outcomes in training and testing cohorts. Secondary endpoints of negative-margin resection and overall survival were also examined. Out-of-sample predictions were then made on a separate ENI-naïve cohort, with similar assessments of selected outcomes. The threshold for statistical significance was set to p < 0.05.
[RESULTS] A total of 1053 patients were identified with a median age of 64.0 years (IQR = 57-70 years). The final model included pancreatic body tumor location, clinical T stage, time from diagnosis to radiation therapy and surgery, ENI dose, and duration of NAC, among others. Patients predicted for treatment response were more likely to be ypN0 (71.5% vs. 29.7%, p < 0.001), had more R0 resections (87.3% vs. 62.6%, p < 0.001), and improved OS after accounting for competing risks of perioperative death (SHR = 0.64, 95% CI = 0.46-0.89, p = 0.008). A similar significant trend was noted in the ENI-naïve cohort (N = 1258). Model AUC was 0.718 and 0.725 in training and testing cohorts, respectively.
[CONCLUSIONS] Using a machine learning approach, we define a nomogram capable of predicting treatment response to multiagent NAC followed by radiotherapy with or without ENI. Patients selected by this model had higher rates of ypN0, higher R0 resection rates, and improved OS.
[METHODS] Using the National Cancer Database (NCDB), we identified patients with cT1-4N0M0 PDAC diagnosed between 2006 and 2020 treated with multiagent NAC, radiation with ENI, followed by curative resection with nodal dissection. A LASSO logistic regression model was used to predict ypN0 status, with generation of a nomogram and assessment of outcomes in training and testing cohorts. Secondary endpoints of negative-margin resection and overall survival were also examined. Out-of-sample predictions were then made on a separate ENI-naïve cohort, with similar assessments of selected outcomes. The threshold for statistical significance was set to p < 0.05.
[RESULTS] A total of 1053 patients were identified with a median age of 64.0 years (IQR = 57-70 years). The final model included pancreatic body tumor location, clinical T stage, time from diagnosis to radiation therapy and surgery, ENI dose, and duration of NAC, among others. Patients predicted for treatment response were more likely to be ypN0 (71.5% vs. 29.7%, p < 0.001), had more R0 resections (87.3% vs. 62.6%, p < 0.001), and improved OS after accounting for competing risks of perioperative death (SHR = 0.64, 95% CI = 0.46-0.89, p = 0.008). A similar significant trend was noted in the ENI-naïve cohort (N = 1258). Model AUC was 0.718 and 0.725 in training and testing cohorts, respectively.
[CONCLUSIONS] Using a machine learning approach, we define a nomogram capable of predicting treatment response to multiagent NAC followed by radiotherapy with or without ENI. Patients selected by this model had higher rates of ypN0, higher R0 resection rates, and improved OS.
MeSH Terms
Humans; Middle Aged; Female; Male; Pancreatic Neoplasms; Aged; Neoadjuvant Therapy; Supervised Machine Learning; Carcinoma, Pancreatic Ductal; Lymphatic Irradiation; Nomograms; Pancreatectomy; Treatment Outcome; Antineoplastic Combined Chemotherapy Protocols